Chapter 4

THE ROLE OF THE EFFLUX TRANSPORTER P-GLYCOPROTEIN IN BRAIN PENETRATION OF PREDNISOLONE

A.M. Karssen
O.C. Meijer
I.C.J. van der Sandt*
A.G. de Boer*
E.C.M. de Lange*
E.R. de Kloet

* Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands.

Reproduced with permission from the Society for Endocrinology
Abstract
The multidrug resistance (mdr) P-glycoprotein (Pgp) functions as a glucocorticoid efflux transporter at the blood-brain barrier. In the present study, we have investigated the role of Pgp in hampering the access of the synthetic glucocorticoid prednisolone to the brain. 

In vivo, a tracer dose of $^3$H-prednisolone poorly penetrated the brain of adrenalectomised wild type mice. In contrast, the uptake was more than three fold enhanced in absence of Pgp expression in mdr1a (-/-) mice. In vitro, in stably transfected LLC-PK1 monolayers the human MDR1 P-glycoprotein was able to transport prednisolone present at a micromolar concentration. This polar transport of $^3$H-prednisolone was blocked by a specific Pgp blocker. Human Pgp does not transport all steroids, as cortexolone was not at all transported and aldosterone was only weakly transported.

The ability of Pgp to export the synthetic glucocorticoid prednisolone suggests that uptake of prednisolone in human brain is impaired, leading to a discrepancy between central and peripheral actions. Furthermore, the ensuing imbalance in activation of the two types of brain corticosteroid receptors may have consequences for cognitive performance and mood.
Introduction

The synthetic glucocorticoids prednisolone and dexamethasone are widely used as anti-inflammatory and immunosuppressive drugs, because of their potent glucocorticoid actions in combination with their low mineralocorticoid (salt-retaining) actions. These actions are mediated by glucocorticoid receptors (GR) and mineralocorticoid receptors (MR), respectively (De Kloet et al., 1998). Both types of corticosteroid receptors are present in the brain, where they play important roles in mediating glucocorticoid actions on brain function. Treatment with synthetic glucocorticoids, therefore, has major effects on cognitive function (Belanoff et al., 2001), whereas blockade of GR action seems to be a promising anti-depression strategy (Belanoff et al., 2002). Glucocorticoids are commonly believed to cross endothelial barriers with relative ease because of their highly lipophilic nature and their small size. However, we recently demonstrated that the penetration of dexamethasone into mouse brain is hampered because the multidrug resistance 1a (mdr1a) P-glycoprotein (Pgp) excludes this high affinity GR ligand from brain (Schinkel et al., 1995; Meijer et al., 1998). The drug-transporting Pgp is expressed at the luminal membranes of endothelial cells of the blood brain barrier (BBB) (Cordon-Cardo et al., 1989; Thiebaut et al., 1989). This transmembrane protein is encoded by the mdr1a gene in rodents and by the highly homologous MDR1 gene in humans (Jette et al., 1995; Van de Vrie et al., 1998). We hypothesised that the synthetic GR ligand prednisolone is a substrate of this efflux transporter as well and is thus hampered in its ability to enter the glucocorticoid target areas in the brain. A poor penetration of the BBB by this synthetic glucocorticoid may have important implications for its actions on brain function.

Pgp mediated transport is not a common feature of each steroid. We have examined Pgp mediated transport of several naturally occurring corticosteroids. Recently, we have shown that there is a large difference in transport between the mixed MR/GR agonists cortisol and corticosterone (Karssen et al., 2001). Cortisol is transported by human MDR1 Pgp and, in line with the presence of MDR1 Pgp at the BBB, the levels of cortisol in human brain are decreased towards those of corticosterone. In contrast, the latter compound freely crosses the BBB in rodents as well as man (Karssen et al., 2001). We now demonstrate the lack of robust Pgp mediated transport for two other corticosteroids, which are circulating in human plasma, i.e. the high affinity MR ligand aldosterone and the precursor of cortisol, 11-deoxycorticisol (cortisolone).

We have tested our main hypothesis about the role of Pgp at the BBB in reducing the penetration of prednisolone into brain in two ways. First, we tested whether mdr1a Pgp at the mouse BBB limits in vivo brain penetration and retention of prednisolone. For this purpose we have injected adrenalectomised mdr1a (-/-) and wild type mice with 3H-prednisolone with or without pretreatment with excess of unlabelled prednisolone. Secondly, we investigated in vitro whether the human homologue, MDR1 Pgp, is also able to transport prednisolone.
Therefore, we have measured polar transport of prednisolone in monolayers of pig kidney epithelial cells stably transfected with human MDR1 cDNA in comparison with nontransfected host cells.

**Materials and methods**

**In vivo distribution and autoradiography**

The *in vivo* distribution experiments were carried out as described previously (Meijer et al., 1998; Karssen et al., 2001) with some modifications. Male mdr1a (-/-) and wild-type Friends virus B (FVB) mice were bred under SPF conditions at TNO (Leiden, The Netherlands). Male mice at the age of 18-23 weeks were used for this study. All experiments were carried out in accordance with the European Communities Council Directive 86/609/EEC and with approval from the animal care committee of the Faculty of Medicine, Leiden University (Leiden, The Netherlands).

After transport, the mice were housed individually at our laboratory, at ambient temperature and at a 12/12 hour lighting schedule (lights on at 0700 h, lights off at 1900 h) with free access to food and water.

To remove the source of endogenous corticosterone, mice were bilaterally adrenalectomised under gas anaesthesia (isoflurane) by a dorsal approach. After adrenalectomy (ADX) the animals had free access to 0.9% saline. At the time of the experiment the animals weighed 28 ± 2.0 gr. (mean ±SD). Two days after ADX, the animals were subcutaneously injected with tritiated prednisolone (dissolved in 2% ethanol/0.9% saline) for *in vivo* distribution. Wild type (n=9) and mutant mice (n=6) were injected with 3.5 µCi/10 gr (2,4,6,7)-3H-prednisolone (Amersham Pharmacia Biotech, UK, specific activity (S.A.) 48 Ci/mmol). For *in vivo* autoradiography mice (n=2) were treated with 13.5 µCi/10 gr 3H-prednisolone in a separate but similar experiment. As a control for non-specific retention, one mouse of each genotype was pretreated with a 100-fold excess of unlabelled prednisolone (Sigma-Aldrich, Germany).

One hour after injection the animals were decapitated. Trunk blood was collected in EDTA-coated tubes and centrifuged for determination of radioactivity and of remaining corticosterone in the plasma using a 125I-corticosterone radioimmunoassay kit (ICN Biomedicals, Costa Mesa, USA.). The brain was dissected and quickly frozen in isopentane precooled on dry ice/ethanol. Liver, testis, intestine and cerebellum were dissected and frozen on dry ice. All tissues were stored at –80 °C until further use.

All organ tissues studied, except for the brain, were homogenised using Soluene-350 (Packard Bioscience, Groningen, The Netherlands). Hionic-Flou (Packard Bioscience) was added to tissue homogenates and plasma and radioactivity was determined in a Tricarb ß-counter (Packard Instruments, Meriden, U.S.A.). Twelve-micrometer coronal sections of brain were cut on a cryostat and thaw-mounted on poly-L-lysine (Sigma Chemical Co., St Louis, USA) coated microscopic slides. The slides were put in an X-ray exposure holder (Amersham Pharmacia Biotech) and apposed to Ultrofilm (Leica Corp., Heerbrugg, Switzerland) for 18 months.
Transepithelial transport and inhibition studies

In order to examine the interactions of the glucocorticoid prednisolone, the mineralocorticoid aldosterone and partial antiglucocorticoid cortexolone with the human P-glycoprotein we used monolayers of the porcine kidney epithelial cell-line LLC-PK1 and LLC-PK1 cells stably transfected with cDNA of the human MDR1 gene (LLC-PK1:MDR1). Cells originally obtained from the American Type Culture Collection (Manassas, USA) were kindly provided by the Dutch Cancer Institute (Amsterdam, The Netherlands) (Schinkel et al., 1995). Human P-glycoprotein has been shown before to be specifically expressed on the apical surface of LLC:PK1:MDR1 cells in these monolayers (Ueda et al., 1992; Florea et al., 2001). Therefore, Pgp substrates entering these cells from the basal side will be translocated to the apical compartment, while those entering the apical membrane will be pumped back into the medium, thus resulting in polarised transport of substrates. This system models the way Pgp is likely to function at the BBB in excluding drugs from the brain (Yamazaki et al., 2001).

Cells were cultured at 37 °C in the presence of 5% CO₂ in complete medium, which consisted of DMEM (BioWhittaker, Verviers, Belgium) supplied with 25 mM HEPES and 4.5 g/l glucose and supplemented with 100.000 U/l penicillin, 100 mg/l streptomycin, 2 mM L-glutamine and 10% (vol/vol) foetal calf serum. The LLC-PK1 and LLC-PK1:MDR1 cell lines were subcultured by trypsinisation every 3 to 4 days and medium was replaced twice a week. During the experiments complete medium was used. The LLC-PK1 and LLC-PK1:MDR1 cells were seeded on microporous polycarbonate membrane filters (0.4 µM pore size, 12 mm diameter, Transwell™; Costar, Cambridge, USA) at a density of 120*10³ cells/cm². The cells were grown for 5-6 days in complete medium with a medium replacement at day 3. Two hours before the start of the experiment, the medium was replaced with 800 µl fresh medium at both the apical and basal side of the monolayer. In the inhibition experiments, one hour later the potent and selective P-glycoprotein blocker LY 335979 (1 µM in water; kindly provided by Eli Lilly, USA) or water was added at the basal side. To measure the transepithelial transport from the apical to the basal side or from the basal to the apical side 8 µl of a 100x stock of tritiated steroid in ethanol was added in triplicate at the apical or basal side respectively, at the start of the experiment (t=0). We have tested \(^3\)H-prednisolone, and (1,2,6,7)-\(^3\)H-aldosterone (Amersham Pharmacia Biotech, S.A. 64 Ci/mmol), (1,2(n))-\(^3\)H-deoxycortisol (=cortexolone; NEN Life Science Products, Boston, USA, S.A. 57 Ci/mmol) and, as a positive control, (1,2,4,6,7)-\(^3\)H-dexamethasone (Amersham Pharmacia Biotech, S.A. 91 Ci/mmol). As we were interested whether MDR1 Pgp was able to transport prednisolone even at high concentrations we supplemented \(^3\)H-prednisolone with 1 µM unlabelled prednisolone. The starting concentrations for each experiment are mentioned in the legends of the corresponding figures.

Over the four hours of study 75 µl aliquots were taken once every hour from both compartments. Eight µl samples of the 100x stock, and samples from the compartment opposite the one to which activity was added, were counted in a Tricarb β-counter after adding 3 ml Emulsifier Safe (Packard). Basal to apical and apical to basal transport is presented as percentage of total radioactivity added at the beginning of the experiment. Transepithelial
electrical resistance was measured before and after the experiments to check the integrity of the monolayers (Gaillard and De Boer, 2000).

Statistical analysis
Mouse data were evaluated by Student’s t-test. The results of the monolayer experiments were analysed by repeated measures ANOVA. Significance was taken at p < 0.05.

**Figure 1.** Representative autoradiograms of 12-µm coronal sections of the brain demonstrate the large difference in uptake of $^3$H-prednisolone in wild type (A) and mdr1a (-/-) mouse (B) brains one hour after administration of 13.5 µCi/10 gr. body weight. The dark spots in (A) represent transverse sectioning of the cerebroventricular space and adjacent ventricular walls. Pretreatment with unlabelled prednisolone abolishes specific hippocampal labelling in mdr1a (-/-) mouse brain but does not affect the labelling of the rest of the brain (C).
Results

Difference in $^3$H-prednisolone brain uptake in mdr1a(-/-) and wild type mice

One hour after administration of $^3$H-prednisolone to ADX mice, the uptake of radioactivity in brain showed a clear difference between mdr1a (-/-) mice and wild type mice. After injection with 2.5 µg/kg radiolabelled prednisolone the amount of radioactivity in cerebellum homogenates was 3.2-fold higher in mutants than in wild types (table 1). The plasma levels of radioactivity were similar and the concentrations in the liver or any other peripheral tissue examined were not significantly different between both genotypes (table 1). Comparable results were obtained after administration of 10 µg/kg $^3$H-prednisolone (table 2). Although absolute levels in all tissues and blood were obviously higher after this higher dose, the brain-to-blood ratios were not significantly different from the ratios obtained after administration of the lower dose. Remarkably, pretreatment with unlabelled prednisolone does not lead to any change in uptake of radioactivity in cerebellum (tables 1 and 2).

The autoradiograms also clearly demonstrate the difference between knockouts and controls. The mdr1a (+/+ ) animals showed negligable labelling of brain tissue after administration of $^3$H-prednisolone (figure 1A). Labelling in brain sections was restricted to the cerebral ventricles. Some radioactive label seemed to have penetrated into the brain tissue around the ventricles, but the amount was considerably lower compared to the amount taken up by the

| TABLE 1. Uptake of radioactivity in tissue homogenates and blood 1 hr after administration of 2.5 µg/kg $^3$H-prednisolone without or with pretreatment with 100-fold excess unlabelled prednisolone |
|-------------------------------------------------|-----------------|---------------|
| Prednisolone | dose 2.5 µg/kg | mdr1a (-/-)   |
| N | cerebellum [nCi/mg] | 7 | 5 | 0.010 ± 0.001 | 0.030 ± 0.001 * |
| N | plasma [nCi/µl] | 0.046 ± 0.004 | 0.044 ± 0.001 |
| N | liver [nCi/mg] | 1.500 ± 0.086 | 1.631 ± 0.160 |
| N | testis [nCi/mg] | 0.031 ± 0.001 | 0.034 ± 0.004 |
| N | intestine [nCi/mg] | 0.779 ± 0.198 | 0.937 ± 0.305 |
| N | brain/blood ratio | 0.226 ± 0.027 | 0.708 ± 0.023 * |

Pretreatment with 0.25 mg/kg unlabelled prednisolone

| N | cerebellum [nCi/mg] | 2 | 1 | 0.009 ± 0.001 | 0.031 |
| N | plasma [nCi/µl] | 0.040 ± 0.003 | 0.038 |
| N | liver [nCi/mg] | 1.951 ± 0.533 | 2.191 |
| N | brain/blood ratio | 0.222 ± 0.002 | 0.796 |

* p < 0.01 compared to wild type
brain of mdr1a (-/-) mice. These mutant mice showed increased labelling of whole brain (figure 1B). In particular, radioactivity was retained in the paraventricular nucleus (PVN) and hippocampal cell fields. These brain areas abundantly express GRs. Pretreatment with a 100-fold excess of unlabelled prednisolone prevents this specific labelling (figure 1C). Remarkably, this pretreatment does not affect the labelling of the rest of the brain as was also shown in the cerebellum homogenates. Thus, disruption of the mdr1a gene leads to enhanced uptake of prednisolone into the brain. High-dose pretreatment did not abolish this effect. Accordingly, these data clearly demonstrate that the presence of mdr1a Pgp in the BBB hampers the access of prednisolone to the mouse brain, particularly to the target areas within the brain that abundantly express GR.

Transepithelial transport of prednisolone in LLC-PK1 and MDR1 monolayers
To test whether the human homologue of the mdr1a Pgp, MDR1 Pgp, is also able to transport prednisolone, we studied the transport capabilities of monolayers of pig kidney cells stably transfected with human MDR1 cDNA. For comparison, we also examined prednisolone transport in monolayers of untransfected cells. Unlabelled prednisolone (1µM) supplemented with a tracer dose of ³H-prednisolone was added to the basal or apical compartment. Prednisolone was transported in a clear polarised fashion in the MDR1 transfected monolayers, but not in monolayers of the parental cells (figure 2A), indicating that the human Pgp is able to transport prednisolone, even at the high concentration tested. Polarised transport in MDR1 monolayers of prednisolone was abolished in presence of LY335979, a potent and selective Pgp blocker (Starling et al., 1997; Dantzig et al., 1999), resulting in similar fractions transported as in monolayers of untransfected cells (figure 2B). This confirms that prednisolone transport is largely mediated by human P-glycoprotein.

<table>
<thead>
<tr>
<th>Pretreatment 1mg/kg</th>
<th>wild type</th>
<th>mdr1a (-/-)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 / 1</td>
<td>1 / 1</td>
</tr>
<tr>
<td>Prednisolone dose</td>
<td>10 µg/kg</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>1 / 1</td>
<td>1 / 1</td>
</tr>
<tr>
<td>cerebellum [nCi/mg]</td>
<td>0.040 / 0.061</td>
<td>0.246 / 0.204</td>
</tr>
<tr>
<td>plasma [nCi/µl]</td>
<td>0.212 / 0.282</td>
<td>0.371 / 0.303</td>
</tr>
<tr>
<td>liver [nCi/mg]</td>
<td>6.277 / 8.647</td>
<td>11.22 / 7.657</td>
</tr>
<tr>
<td>brain/blood ratio</td>
<td>0.189 / 0.216</td>
<td>0.664 / 0.673</td>
</tr>
</tbody>
</table>

TABLE 2. Uptake of radioactivity in tissue homogenates and blood 1 hr after administration of 10 µg/kg ³H-prednisolone without (-) or with (+) pretreatment with 100-fold excess unlabelled prednisolone.
As a positive control, we also assessed transepithelial transport of dexamethasone in our monolayers and demonstrated that MDR1 Pgp also efficiently transports this synthetic glucocorticoid (data not shown), as has been shown previously (Ueda et al., 1992; Schinkel et al., 1995).

Transepithelial transport of naturally occurring steroids

We further examined Pgp-mediated transport of corticosteroids that are naturally occurring in humans. Previously we published the marked difference between Pgp-mediated cortisol and corticosterone transport (Karssen et al., 2001). Now we focused on two additional corticosteroids, cortexolone and aldosterone. Cortexolone transport in the MDR1 transfected monolayers was not different from transport in monolayers of control cells (figure 3A), indicating the absence of human MDR1 Pgp mediated transport of cortexolone. Although polarised transport was observed in both cell lines, this is likely caused by other renal transporters. Administration of LY335979 did not change the fraction of cortexolone translocated through the membrane (figure 3B), confirming the lack of Pgp contribution to the transport of cortexolone.
Examination of the transport of aldosterone shows that, although aldosterone displayed polarised transport in both transfected and parental monolayers, there was a small but significant MDR1 Pgp contribution (figure 3C). This Pgp mediated transport could be partly blocked by LY335979 (figure 3D). These results demonstrate that aldosterone is only weakly transported by MDR1 Pgp.
Discussion

The present study indicates that the efflux transporter Pgp at the level of the BBB decreases the degree of brain exposure to the synthetic glucocorticoid prednisolone. Our in vivo autoradiography data show that the mdr1a Pgp present at the BBB hampers the penetration of \(^3\)H-prednisolone into the mouse brain, whereas our results with monolayers of human MDR1 cDNA transfected LLC-PK1 cells suggest that Pgp may export prednisolone from human brain as well. We further demonstrated that aldosterone is transported by Pgp to a much smaller extent, while cortexolone is not at all transported.

Cells expressing P-glycoproteins are able to exclude a wide variety of structurally and functionally unrelated drugs, a phenomenon called multidrug resistance (Van de Vrie et al., 1998). It is now well established that Pgp is expressed in many normal tissues including the intestinal epithelium, the adrenals and brain capillary endothelial cells (Schinkel, 1999). Several steroids such as dexamethasone and cortisol but not corticosterone are among its substrates (Ueda et al., 1992; Bourgeois et al., 1993; Ueda et al., 1996; Karssen et al., 2001). In the last decade, several studies have established the Pgp mediated transport of the widely used synthetic glucocorticoid, dexamethasone. Pgp overexpressing cells accumulate reduced amounts of dexamethasone (Barnes et al., 1996), while the steroid is transported in a polarised fashion in monolayers of LLC-PK1 cells transfected with MDR1 cDNA (Ueda et al., 1992; Schinkel et al., 1995, this study; Karssen et al., 2003). Furthermore, penetration of dexamethasone into mdr1a (-/-) mouse brain is enhanced compared to wild type brain (Schinkel et al., 1995) increasing its access to the glucocorticoid receptor (Meijer et al., 1998).

While dexamethasone transport by Pgp has thus been convincingly demonstrated, information about Pgp mediated transport of prednisolone is sparse. Bourgeois et al. (1993) have shown that murine thymoma cells expressing mdr1b Pgp are resistant to prednisolone (and dexamethasone) induced apoptosis, but this second murine multidrug resistance Pgp is not expressed at the BBB. Our study clearly shows that both mouse mdr1a and human MDR1 Pgp transport prednisolone, as has been shown previously for dexamethasone and cortisol. This implicates that any GR expressing cell type that also express the efflux transporter Pgp is resistant to these glucocorticoids, which is in line with recent results of Pariante et al. (2001).

In contrast to these glucocorticoids, Pgp does not transport corticosterone (Karssen et al., 2001), a glucocorticoid that also circulates in human plasma but at 10 fold lower levels than cortisol, and some other naturally occurring steroids. In line with the presence of MDR1 Pgp at the BBB the levels of cortisol in human brain are decreased towards the brain levels of corticosterone as measured in post mortem specimens with liquid chromatography-mass spectrometry (LC-MS) (Karssen et al., 2001). We now demonstrate that Pgp is also unable to transport cortexolone, which is a weak partial agonist/antagonist at the GR in vitro (Kaiser and Mayer, 1980; Schmidt and Davidson, 1987) and in vivo (Acs and Stark, 1975; Duncan and Duncan, 1979; Kaiser and Mayer, 1980). In addition, the high affinity MR ligand aldosterone
is only weakly transported by Pgp in our MDR1-monolayers. These results agree with several in vitro studies on Pgp mediated transport of aldosterone. Using comparable monolayers to those in this study, Ueda et al. (1992) have demonstrated that aldosterone is moderately transported by the human MDR1 Pgp, while Bourgeois et al. (1993) showed that corticosterone was not and aldosterone was only weakly transported by mdr1b Pgp.

Although prednisolone is among the most common clinically used glucocorticoids, this study is one of the first that has examined the fate of prednisolone in brain, whereas other major glucocorticoids have been extensively studied before (for review see McEwen et al., 1986a). In contrast to uptake into the brain of both corticosterone and aldosterone (McEwen et al., 1968; De Kloet et al., 1975; McEwen et al., 1976; De Nicola et al., 1981; Coutard et al., 1987), access of dexamethasone and cortisol to brain is impaired (De Kloet et al., 1974; De Kloet et al., 1975; Rees et al., 1975; McEwen et al., 1976), because of the presence of Pgp at the BBB (Meijer et al., 1998; Karssen et al., 2001). We now demonstrate that prednisolone is also hampered to reach the brain due to the presence of Pgp at this barrier. The active exclusion from the brain provides an explanation for the long-established puzzling phenomenon that GR in the brain is not labelled after in vivo administration of tracer doses of synthetic GR ligands.

In mdr1a null mice the high affinity GR-ligand prednisolone is retained by hippocampal and paraventricular neurons as expected based on localisation of GR expressing cells (Van Eekelen et al., 1987). Among the hippocampal subfields, the CA3 pyramidal layer retained the lowest amount of label, in accordance with the neuro-anatomical distribution of hippocampal GR as measured with immunohistochemistry and in situ hybridisation (Van Eekelen et al., 1987; Van Eekelen et al., 1988). Pretreatment of mice with 100-fold excess of unlabeled prednisolone abolishes this selective retention in hippocampal cells and PVN, but does not affect the overall uptake elsewhere in the brain. This indicates that the uniform labelling of the rest of the brain may be due mainly to non-receptor bound, freely moving prednisolone masking specific nuclear retention of low abundantly expressed GR in many parts of the brain.

Prednisolone, like dexamethasone, can bind to MR in vitro, but the affinity to this receptor is much lower than to GR to which these steroids bind with very high affinity (< 1 nM) (Lan et al., 1981; Lan et al., 1982; De Kloet et al., 1984a). In contrast corticosterone and cortisol bind with high affinity to MR (< 1 nM) and with tenfold lower affinity to GR. In line with this low affinity to the MR prednisolone has only minor effects on salt retention in the kidney (Karssen and De Kloet, 2000). Using in vivo autoradiography only very high affinity receptors can be visualised due to the low doses used (De Kloet, 1991); e.g. in mdr1a (-/-) mice only MR can be made visible with $^3$H-cortisol autoradiography as is the case with $^3$H-corticosterone in both wild type and mutant mice (Karssen et al., 2001). In this study, prednisolone is only able to visualise GR while the MR has a too low affinity for this steroid to be detectable.
Pgp hampers prednisolone brain access

The lack of effect of pretreatment of unlabeled prednisolone on uptake of $^3$H-prednisolone in wild type brain indicates that the capacity of Pgp to expel prednisolone from brain is rather high. Furthermore, the monolayer results using 1 µM prednisolone also suggest that even at high concentrations Pgp is able to reduce prednisolone concentrations in the brain. Interestingly, a recent study was not able to detect prednisolone in guinea pig brain, in contrast to liver and plasma, at various time points after administration of a high dose of 100 mg/kg (Tobita et al., 2002). Therapeutically prednisolone is used in high doses in the treatment of diverse medical conditions, including pulmonary, rheumatologic, neurological and autoimmune diseases and immune suppression following organ transplantation. Our results suggest that in humans treated with prednisolone, the resultant glucocorticoid levels in brain would be considerably lower than plasma levels. As most peripheral tissues are not protected by a Pgp expressing barrier, peripheral effects would therefore be relatively more potent than central effects, although this does not preclude central effects of prednisolone.

Hippocampal-dependent memory impairment after long-term high dose treatment with prednisone (which is quickly converted to prednisolone in vivo) has been described (Keenan et al., 1996). As hippocampal GR is involved in memory performance (Oitzl and De Kloet, 1992), these effects could be attributed to activation of this receptor. On the other hand, an imbalance in central MR and GR activation as a result of prednisolone treatment could provide an alternative explanation. Differential effects mediated by MR and GR activation on cognitive function have been proposed (De Kloet et al., 1999; Lupien and Lepage, 2001). Although mainly based on animal studies, De Kloet et al. (1991; 1999) have postulated that a balance between MR and GR mediated effects critically determines human cognitive functioning. Whether prednisolone reaches the brain or not, due to the prednisolone induced suppression of pituitary-adrenal activity and thus of adrenocortical secretion, the brain becomes deprived of the endogenous glucocorticoids, corticosterone and cortisol. As a consequence, the ratio of MR/GR occupation will shift towards GR occupation with consequences for cognitive performance, mood and regulation of the behavioural stress response.

As many different drugs used in the clinic are Pgp substrates as well, one has to be aware of undesired side effects when prednisolone (or dexamethasone) is used in conjunction with these drugs. Cotreatment may be able to enhance the brain uptake of the synthetic glucocorticoid. The potent immunosuppressants FK506 and cyclosporine A have been shown to potentiate dexamethasone but not corticosterone mediated transcriptional activity apparently due to inhibition of a MDR pump similar to Pgp (Medh et al., 1998). The facilitation of prednisolone’s poor penetration into the brain by anti-cancer drugs may also give a rationale to the reported success of combination therapy in treatment of different types of brain tumours (Wu et al., 1999; Shibamoto et al., 1999; Maipang and Janjindamai, 2000). Many anti-cancer drugs (e.g. Vinca alkaloids, anthracyclines, and taxanes) are known to be
Pgp substrates. In fact, the first reports of Pgp expression dealt with tumour cells developing multidrug resistance after treatment with a single cytotoxic drug. Further treatment of these tumours is difficult. Provided that the tumour does not disrupt the BBB, brain tumours are even intrinsically resistant to these drugs, as they are behind the BBB (Regina et al., 2001). A combination of prednisolone and other drugs, that are all Pgp substrates, may mutually increase their active brain levels by saturating Pgp.

In conclusion, we have demonstrated the involvement of Pgp in hampering the access of the synthetic glucocorticoid prednisolone to mouse brain. The ability of the human MDR1 Pgp to transport prednisolone suggests that prednisolone access to human brain is also impeded. The poor penetration of prednisolone into human brain would presumably lead to a discrepancy in the extent of central and peripheral actions of prednisolone. The subsequent imbalance in MR and GR activation may explain the reported changes in cognitive performance and mood in response to prednisone/prednisolone therapy.

Acknowledgements

Marc Fluttert, Sergiu Dalm and Dirk-Jan van den Berg are gratefully acknowledged for animal handling and technical assistance. We are further grateful to Margret Blom and Heleen Voorwinden for assistance with cell cultures.